WO2025210605 - CANNABIDIOL COMPOSITIONS FOR ANXIETY DISORDERS
National phase entry is expected:
Publication Number
WO/2025/210605
Publication Date
09.10.2025
International Application No.
PCT/IB2025/053618
International Filing Date
05.04.2025
Title **
[English]
CANNABIDIOL COMPOSITIONS FOR ANXIETY DISORDERS
[French]
COMPOSITIONS DE CANNABIDIOL CONTRE DES TROUBLES DE L'ANXIÉTÉ
Applicants **
LEIUTIS PHARMACEUTICALS LLP
Inventors
KOCHERLAKOTA, Chandrashekhar
BANDA, Nagaraju
NARALA, Arjun
PULLAGURA, Naga Udaya Sankar
AKULA, Srinath
Priority Data
202441028160
05.04.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1956 | |
| EPO | Filing, Examination, Granting | 11788 | |
| Japan | Filing, Examination, Granting | 2046 | |
| South Korea | Filing, Examination, Granting | 1777 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,307
Contact Us
Abstract[English]
The present invention relates to pharmaceutical compositions of cannabidiol comprising less than 0.3% of THC for treating various anxiety disorders. The invention also discloses evaluation of efficacy, safety and pharmacokinetics of these compositions for treating mild to moderate anxiety disorders.[French]
La présente invention concerne des compositions pharmaceutiques de cannabidiol comprenant moins de 0,3 % de THC pour traiter divers troubles de l'anxiété. L'invention concerne également l'évaluation de l'efficacité, de la sécurité et de la pharmacocinétique de ces compositions pour traiter des troubles de l'anxiété légers à modérés.